[
  {
    "clause_index": 7,
    "start_char": 2515,
    "end_char": 2560,
    "original": "NOW, THEREFORE, the Parties agree as follows:",
    "ollama_generated": "NOW, THEREFORE, the Parties mutually understand and agree as follows:\n\nWith a spirit of cooperation and good faith, it shall be incumbent upon Party B, in the event that circumstances necessitate such action, to make reasonable efforts to mitigate any potential issues arising from their obligations under this agreement. Party A shall not be held responsible for any unavoidable consequences stemming from Party B's failure to meet these obligations, provided that Party A has acted in accordance with the spirit and purpose of this agreement.",
    "contradiction_score": 0.005649525672197342,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 8,
    "start_char": 2560,
    "end_char": 2883,
    "original": "1. SCOPE AND AREAS OF THE JV The Parties wish to collaborate to the Joint Venture (\u201cJV\u201d), with their respective efforts and possibilities of support, assistance, advice, co-operation,  and resources for the common purposes about the research and development of the pre-clinical  and clinical trial programs mentioned above.",
    "ollama_generated": "1. SCOPE AND LIMITATIONS OF THE JV The Parties opt to engage in the Joint Venture (\"JV\"), with a shared understanding that their individual contributions, resources, and cooperation will be directed primarily towards the research and development of the pre-clinical and clinical trial programs outlined herein, but without any implied obligation or undertaking beyond what is explicitly stated. The Parties acknowledge that they retain the ultimate responsibility for the management and decision-making within their respective areas of control, and neither Party shall be held liable for any actions, inactions, or outcomes resulting from the other Party's sphere of operation.",
    "contradiction_score": 0.15018688142299652,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 13,
    "start_char": 4048,
    "end_char": 4293,
    "original": "- Kiromic is committed to sharing patents and know-how  in relation to the following products which will be licensed to the JV exclusively for the application in the specific and limited field of sars-cov-2  threat and relative disease COVID-19:",
    "ollama_generated": "In accordance with this agreement, Kiromic grants an exclusive license to the Joint Venture for the utilization of patents and know-how specifically pertaining to products designed for combating the SARS-CoV-2 threat and associated disease, COVID-19. It is understood that such licensing is contingent upon Kiromic's discretion and may be withheld or modified at any time, without breaching this agreement.",
    "contradiction_score": 0.0047297487035393715,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 22,
    "start_char": 7966,
    "end_char": 8129,
    "original": "4. JV FUND Kiromic undertakes to financially support the entire research program in oncology\u037e By way of example, Kiromic undertakes to finance the following items:",
    "ollama_generated": "4. Collaboratively Spearheading Oncology Research: The JV Fund Kiromic commits to jointly financing the entire research program in oncology; For illustrative purposes, it is understood that Kiromic's financial contributions will be directed towards the following aspects of the project:\n\nThis revised clause weakens the obligation slightly by introducing a collaborative approach instead of sole financial responsibility. It also shifts the language to reflect joint effort and mutual agreement on financial contributions.",
    "contradiction_score": 0.031040173023939133,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 26,
    "start_char": 9179,
    "end_char": 9383,
    "original": "By way of example, Molipharma undertakes to finance the following items, either directly or indirectly through research grants or other non-diluting funds, awarded by European and/or Italian Institutions:",
    "modified": "For illustrative purposes, Molipharma assumes no obligation to provide financing for the specified items, but instead may seek funding from European and/or Italian Institutions in the form of research grants or non-diluting funds, with the understanding that such funds may indirectly support the aforementioned expenses.",
    "contradiction_score": 0.9200435876846313,
    "kept": true
  },
  {
    "clause_index": 29,
    "start_char": 10245,
    "end_char": 10621,
    "original": "5. STAFF ACCESS Molipharma allows Kiromic\u2019s staff in charge of the above research programs to have access to its own structures, identified from time to time, as well as the possible use of its own equipment, in compliance with the law provisions and the regulations therein applied, in compliance and observance of the protection, safety and health standards therein applied.",
    "ollama_generated": "5. ACCESS TO MOLIPHARMA FACILITIES: Kiromic grants Molipharma's staff responsible for the specified research projects the right to access and utilize Molipharma's facilities, identified as necessary, subject to compliance with applicable laws and regulations. The use of these facilities is conditioned upon adherence to Molipharma's safety, health, and protection standards, and Kiromic shall be responsible for ensuring that its staff complies with these requirements.",
    "contradiction_score": 0.020193977281451225,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 34,
    "start_char": 11782,
    "end_char": 12383,
    "original": "The Industrial Property Rights on the Results, as well as the Intellectual Property Rights realized in the research activities covered by this JV, are due jointly to the parties in equal shares (50% for each Party), without prejudice to the possibility of agreeing in writing, during the course of every specific activity, about the modification of the respective shares of co-ownership,  based upon the actual contribution of each of the Parties to the research activities, and also without prejudice to the recognition of the intellectual rights due to each inventor pursuant to current legislation.",
    "ollama_generated": "The Industrial Property Rights on the Results, as well as the Intellectual Property Rights derived from the research activities covered by this Joint Venture, shall initially be held equally by the parties (50% for each Party). However, the parties reserve the right to modify their respective shares of co-ownership in writing, should there be an unequal contribution made by either party to the research activities. It is understood that such modifications do not affect the recognition of intellectual rights granted to each inventor under current legislation.",
    "contradiction_score": 0.0028870217502117157,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 46,
    "start_char": 15318,
    "end_char": 15386,
    "original": "Oncology All economics rights are solely owned by Kiromic Biopharma.",
    "ollama_generated": "Economics Rights Assignment:\nThe ownership of all economic rights pertaining to oncology is hereby assigned exclusively to Kiromic Biopharma, with the understanding that this assignment may be subject to any third-party interests or claims that may arise during the term of this agreement.",
    "contradiction_score": 0.012734194286167622,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 58,
    "start_char": 17307,
    "end_char": 17502,
    "original": "a. Breach of confidentiality obligations\u037e b. Unilateral and unagreed variation of the Scope of the JV\u037e c. Failure of each Party to comply with its obligations, including the economic commitments.",
    "ollama_generated": "a. Disclosure of confidential information without express consent or legally mandated disclosure\u037e b. Unilateral actions that expand or alter the Scope of the JV without mutual agreement\u037e c. Neglect by either Party to fulfill its contractual obligations, with particular regard to the economic commitments being optional and not binding unless explicitly agreed upon in writing.",
    "contradiction_score": 0.0024604073259979486,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 65,
    "start_char": 20078,
    "end_char": 20543,
    "original": "12. GENERAL PROVISIONS All notices, demands, requests or other communications which may be or are required to be given, served or sent by any Party to any other Party pursuant to this JV Agreement shall be in writing and shall be hand delivered, sent by DHL (or by comparable international air courier) or mailed by first- class, registered or certified mail, return receipt requested, postage prepaid, or transmitted by telecopy, and shall be addressed as follows:",
    "ollama_generated": "12. GENERAL PROVISIONS: All notices, demands, requests, or communications required under this Joint Venture Agreement may be given, served, or sent by any Party to another Party via email with confirmation of receipt, courier service (such as DHL), or registered post, but failure to receive such communication due to incorrect email address or non-delivery shall not absolve the recipient of their obligations under this agreement.\n\nThe communication should be directed to: [Party's contact information here]\n\nIn case of any dispute regarding the validity and/or delivery of electronic communications, a hard copy sent by registered post with return receipt requested, postage prepaid, shall constitute acceptable proof of service or delivery.",
    "contradiction_score": 0.03578076884150505,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 72,
    "start_char": 23119,
    "end_char": 23553,
    "original": "This JV Agreement cannot be assigned by a Party, also as a result of the transfer of a business as a going concern, of a merger, of a de-merger  or of a spin-off,  without the prior written consent of the other Party. Subject to the above, this JV Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors, heirs, executors, administrators, legal representatives and assigns.",
    "modified": "This Joint Venture Agreement may be assigned by a Party, provided such assignment arises from the transfer of a business as a going concern, a merger, a de-merger, or a spin-off, with the express understanding that such assignment shall only become effective upon receipt of the prior written consent of the other Party. Conversely, the other Party may assign its rights and obligations under this Agreement without requiring the consent of the first Party. This Joint Venture Agreement will continue to bind the Parties hereto and their respective successors, heirs, executors, administrators, legal representatives, and assignees; however, each Party shall remain responsible for any breaches or liabilities incurred prior to such assignment.",
    "contradiction_score": 0.9688511490821838,
    "kept": true
  },
  {
    "clause_index": 73,
    "start_char": 23553,
    "end_char": 24540,
    "original": "Each of the Parties hereby agrees to take or cause to be taken such further actions, to make and receive or cause to be made and received any legal declarations, execute, deliver and file or cause to be executed, delivered and filed such further documents, and will obtain such consents, as may be necessary or as may be reasonably requested in order to fully effectuate the purposes, terms and conditions of this JV Agreement mentioned. Without limiting the generality of the foregoing, in case the Commission of the European Union, or any other competent regulatory authority, both national and supranational, makes the clearance of any of the transactions contemplated by this JV Agreement conditional upon changes or additions to the regulation herein set forth, the Parties shall negotiate in good faith all those amendments that are necessary or proper to comply with such requests by keeping unaltered the spirit of this JV Agreement and the balance of interests herein reflected.",
    "ollama_generated": "Each Party hereto acknowledges and accepts the requirement to undertake or delegate the execution of additional actions, declarations, document preparations, filings, and acquisitions of consents as may be deemed necessary or reasonably suggested, with a view to fully actualizing the intentions, provisions, and stipulations outlined within this Joint Venture Agreement. Notwithstanding the breadth of this provision, in the event that any regulatory body, including but not limited to the Commission of the European Union or any other relevant authority, mandates modifications or supplements to the regulations as a condition for clearing transactions specified herein, the Parties are obliged to engage in good faith negotiations regarding all amendments essential or appropriate for satisfying such requirements, while preserving the fundamental essence and equilibrium of interests as embodied within this Joint Venture Agreement.",
    "contradiction_score": 0.001055562519468367,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 77,
    "start_char": 25637,
    "end_char": 26197,
    "original": "- the customers, suppliers, business, assets or affairs (including financial information) of any Party, including information relating to the marketing of any products or services (for example, customer names and lists and any other details of customers, sales targets, sales statistics, market share statistics, prices, market research reports and surveys and advertising) and other promotional materials\u037e future projects\u037e business development or planning\u037e and commercial relationships or negotiations, but excluding in any case the information in Clause 6.2.",
    "ollama_generated": "- Parties acknowledge that confidentiality extends to all non-public information concerning each Party's customers, suppliers, businesses, assets, affairs (including financial information), marketing strategies and tactics for products or services (including customer data such as names, lists, sales targets, statistics, market share data, pricing details, market research reports, surveys, and advertising materials), future projects, business development plans, commercial negotiations, and commercial relationships. However, this clause shall not apply to the information specified in Clause 6.2. This obligation of confidentiality remains effective even after the termination or expiration of this agreement.",
    "contradiction_score": 0.021795954555273056,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 80,
    "start_char": 26976,
    "end_char": 27605,
    "original": "Each Party irrevocably agrees, undertakes and covenants with the other Party and the Company and any Subsidiary of the Company that it shall at all times keep confidential (and use all reasonable endeavours to ensure that its employees, agents and Associated Companies, and the employees and agents of such Associated Companies, and the Company shall keep confidential) any Confidential Information and shall not use such Confidential Information except for the purpose of exercising or performing its rights and obligations under or in connection with this Agreement, and shall not disclose such Confidential Information except:",
    "ollama_generated": "Each Party irrevocably agrees, undertakes, and covenants with the other Party and the Company, as well as any Subsidiary of the Company, that it shall only retain confidential (and employ all reasonable endeavors to ensure that its employees, agents, and Associated Companies, along with the employees and agents of such Associated Companies, also maintain confidentiality) any Confidential Information. However, this Party may disclose such Confidential Information when required by law or any regulatory authority, or if such disclosure is necessary for the legitimate interests of either Party, provided that prior written consent has been obtained from the disclosing Party in advance, where feasible. The Party shall not use Confidential Information for any purpose other than fulfilling its obligations under this Agreement without prior written consent from the Company.",
    "contradiction_score": 0.0072431499138474464,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 82,
    "start_char": 28967,
    "end_char": 29403,
    "original": "(i) such bank, financial adviser and/or potential Buyer shall first have entered into confidentiality undertakings for the benefit of the Company and any Subsidiary of the Company upon terms no less stringent that those set out in this Clause 10or otherwise in a form reasonably satisfactory to the Board\u037e and (ii) the disclosing Party gives notice to the other Shareholder specifying, in general terms, the information to be disclosed.",
    "ollama_generated": "(i) The other Shareholder shall initially provide written consent for any third party, including but not limited to the bank or financial adviser, to access confidential information of the Company and its Subsidiaries, on terms no less restrictive than those outlined in Clause 10, or on terms mutually agreed upon by both parties and deemed acceptable by said third party. The consent should be granted prior to any such disclosure.\n\n   (ii) Upon granting consent, the other Shareholder shall promptly inform the Board of the specific information that will be disclosed to the aforementioned third party.",
    "contradiction_score": 0.019082356244325638,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 86,
    "start_char": 30196,
    "end_char": 30905,
    "original": "(a) return to the other Party all documents and materials (and any copies) containing, reflecting, incorporating or based on the other Party\u2019s Confidential Information\u037e and (b) erase all the other Party\u2019s Confidential Information from computer and communications systems and devices used by it, including such systems and data storage services provided by third parties (to the extent technically and legally practicable), provided that a recipient party (and/or the Company, as the case may be) may retain documents and materials containing, reflecting, incorporating or based on the other Party\u2019s Confidential Information to the extent required by law or any applicable governmental or regulatory authority.",
    "ollama_generated": "(a) The Receiving Party shall make a reasonable effort to destroy, delete, or anonymize all documents and materials (and any copies thereof) that encompass, represent, incorporate, or are derived from the Disclosing Party's Confidential Information. However, the Retention Obligation shall apply in cases where such retention is mandated by law or any relevant regulatory body.\n\n   (b) The Receiving Party agrees to cleanse its computer and communications systems and devices, as well as any third-party services used for data storage, of the Disclosing Party's Confidential Information to the extent technically and legally feasible. Nevertheless, it is acknowledged that the Receiving Party (and/or the Company, where applicable) may be obligated to maintain documents and materials incorporating the Disclosing Party's Confidential Information in accordance with legal or regulatory requirements.",
    "contradiction_score": 0.16845747828483582,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 93,
    "start_char": 34084,
    "end_char": 34460,
    "original": "15. DATA PROTECTION RULES PURSUANT TO REG.EU 679/2016 (GDPR) Pursuant to and for the purposes of the Privacy Code and EU Reg. 679/2016 (\u201cGDPR\u201d) (\u201cLaw\u201d) on \u201cProtection of persons and other subjects with regard to the processing of personal data\u201d, the Parties - as autonomous Data Controllers - acknowledge that they have exchanged information on the use of their personal data.",
    "ollama_generated": "15. COMPLIANCE WITH DATA PROTECTION REGULATIONS UNDER REG.EU 679/2016 (GDPR) In adherence with and for the fulfillment of the Privacy Code and EU Regulation 679/2016 (\"GDPR\"), hereafter referred to as \"Law\" on \"Protection of persons and other subjects with regard to the processing of personal data\", the Parties, recognizing themselves as independent Data Processors, acknowledge that they have disclosed their respective policies regarding the management and use of personal data.\n\nIn this revised clause, the roles of Data Controller and Data Processor are inverted, which changes the focus of responsibility for compliance with GDPR from one party to another.",
    "contradiction_score": 0.18963220715522766,
    "kept": false,
    "reason": "low_contradiction"
  }
]